Ensysce Biosciences, Inc. (ENSC) Earnings
Ensysce Biosciences, Inc.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Last reported earnings
Aug 13, 2026
From the latest earnings 8-K
Revenue • FY2025
$5.07M
▼ 2.8%YoY
Diluted EPS • FY2025
-$3.98
▲ 65.2%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from ENSC's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $5.07M | -$10.18M | — | -$3.98 | -$7.93M | -202.1% | -2.8% |
| FY2024 | $5.21M | -$7.99M | — | -$11.45 | — | -129.2% | +133.6% |
| FY2023 | $2.23M | -$10.61M | — | -$4.69 | — | -480.5% | -11.6% |
| FY2022 | $2.52M | -$24.17M | — | — | — | -959.9% | -28.5% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 13, 2026 | 8-K (2.02) | 0001493152-26-037794EDGAR |
| May 15, 2026 | 8-K (2.02) | 0001493152-26-023810EDGAR |
| Mar 30, 2026 | 8-K (2.02) | 0001493152-26-013622EDGAR |
| Nov 14, 2025 | 8-K (2.02) | 0001493152-25-023492EDGAR |
| Aug 13, 2025 | 8-K (2.02) | 0001641172-25-023500EDGAR |
| May 13, 2025 | 8-K (2.02) | 0001641172-25-009949EDGAR |
| Mar 10, 2025 | 8-K (2.02) | 0001493152-25-009695EDGAR |
| Nov 12, 2024 | 8-K (2.02) | 0001493152-24-044760EDGAR |
Never miss a ENSC filing.
Get an email when ENSC files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.